A randomized, placebo-controlled, observer-blind, phase 2 study to evaluate safety and immunogenicity of the investigational M72/AS01E Mycobacterium tuberculosis (Mtb) vaccine in virally suppressed, antiretroviral-treated participants with human immunodeficiency virus (HIV).


Published phase 1 and 2 randomized, controlled trials evaluating M72/AS01E vaccination in individuals with HIV who were receiving antiretroviral therapy (ART) show that a 2-dose schedule of the vaccine given one month apart is well-tolerated and immunogenic in this population. This current study intends to confirm that the vaccine is safe, well-tolerated, and immunogenic in a larger population of people with virally suppressed HIV infection in a tuberculosis (TB) endemic region.


  • Prof Lee Fairlie (Principal Investigator)
  • Dr Faeezah Patel (Sub Investigator)
  • Dr Elizea Horne (Sub Investigator)

Latest Update

April 2024

For more about MESA-TB Gates MRI syudy please email

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.